Search

Your search keyword '"Budd, G. Thomas"' showing total 16 results
Start Over Author "Budd, G. Thomas" Publisher wiley
16 results on '"Budd, G. Thomas"'

1. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

Author

Lipton, Allan, primary, Chapman, Judith‐Anne W., additional, Leitzel, Kim, additional, Garg, Ashwani, additional, Pritchard, Kathleen I., additional, Ingle, James N., additional, Budd, G. Thomas, additional, Ellis, Matthew J., additional, Sledge, George W., additional, Rabaglio, Manuela, additional, Han, Lei, additional, Elliott, Catherine R., additional, Shepherd, Lois E., additional, Goss, Paul E., additional, and Ali, Suhail M., additional

Published
2017
Full Text
View/download PDF

2. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer

Author

Donaldson, Alana R., primary, Shetty, Shashirekha, additional, Wang, Zhen, additional, Rivera, Christine L., additional, Portier, Bryce P., additional, Budd, G. Thomas, additional, Downs-Kelly, Erinn, additional, Lanigan, Christopher P., additional, and Calhoun, Benjamin C., additional

Published
2017
Full Text
View/download PDF

3. Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer

Author

Smerage, Jeffrey B., primary, Budd, G. Thomas, additional, Doyle, Gerald V., additional, Brown, Marty, additional, Paoletti, Costanza, additional, Muniz, Maria, additional, Miller, M. Craig, additional, Repollet, Madeline I., additional, Chianese, David A., additional, Connelly, Mark C., additional, Terstappen, Leon W.W.M., additional, and Hayes, Daniel F., additional

Published
2013
Full Text
View/download PDF

16. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.

Author

Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, and Bukowski RM

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Deoxycytidine administration & dosage, Docetaxel, Female, Gastrointestinal Diseases chemically induced, Hematologic Diseases chemically induced, Humans, Male, Maximum Tolerated Dose, Middle Aged, Paclitaxel administration & dosage, Treatment Outcome, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Deoxycytidine analogs & derivatives, Neoplasm Recurrence, Local drug therapy, Neoplasms drug therapy, Paclitaxel analogs & derivatives, Taxoids
Abstract

Background: A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination., Methods: Docetaxel and gemcitabine were administered intravenously on Days 1, 8, and 15 every 28 days. The dose levels of docetaxel and gemcitabine were as follows: Level I, docetaxel 20 mg/m(2)and gemcitabine 400 mg/m(2); Level II, docetaxel 30 mg/m(2)and gemcitabine 400 mg/m(2); Level III, docetaxel 30 mg/m(2)and gemcitabine 600 mg/m(2); Level IV, docetaxel 36 mg/m(2)and gemcitabine 600 mg/m(2); and Level V, docetaxel 36 mg/m(2)and gemcitabine 800 mg/m(2)., Results: Thirty-three eligible patients were entered. The diagnoses were as follows: Eleven patients had nonsmall cell lung carcinoma, 3 patients had carcinoma of the bladder, 3 patients had renal carcinoma, 2 patients had adrenal carcinoma, 5 patients had unknown primary tumors, and 9 patients had miscellaneous malignancies. Fifty-nine percent of patients had received prior chemotherapy. The median age was 62 years (range, 27-77 years), and the median Eastern Cooperative Oncology Group performance status was 1 (range, 0-1). Five patients were treated at Dose Levels I and II, 6 patients were treated at Dose Levels III and V, and 11 patients were treated at Dose Level IV. Grade 3-4 toxicities during Cycle I included neutropenia, thrombocytopenia, mucositis, and diarrhea. Dose-limiting toxicity, consisting of neutropenia and thrombocytopenia, occurred in three of six patients at Dose Level V. The combination of docetaxel 36 mg/m(2) and gemcitabine 600 mg/m(2) (Dose Level IV) was determined as the MTD and was the recommended Phase II dose. Two patients had a partial response: one patient with bladder carcinoma (Dose Level II) and one patient with nonsmall cell lung carcinoma (Dose Level III)., Conclusions: Overall, weekly docetaxel and gemcitabine were well tolerated. Further studies using this combination are planned, including a Phase II trial in patients with advanced nonsmall cell lung carcinoma., (Copyright 2003 American Cancer Society.)

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results